Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy. Patients will often find out when experiencing resting dyspnea, syncope, or signs and symptoms of acute deterioration, such as cardiac failure, referred to as acute decompensated aortic stenosis (ADAS). As we all know, optimal medical treatment in these cases is limited, with poor prognosis at hospital discharge, 30 days and one year. 

This analysis included 276 patients with ADAS; 150 received TAVR within ≤22 days after hospitalization and the rest, beyond this period. 

The primary outcome was hospitalization for cardiac failure or all-cause mortality.

The groups were comparable: mean patient age 84, 63% men, 53% hypertensive, 35% had coronary artery disease, 5% had PCI within 90 days prior TAVR, 26% had diabetes, 58% kidney function deterioration, 23% COPD and estimated glomerular filtration rate (eGFR) was 55 ml/min. Mean EuroSCORE was 6,5% and 3% required cardiopulmonary support.

Mean ejection fraction was 55%; 15% presented ejection fraction <30%. There were no differences in aortic valve area, gradients, velocity or presence of mitral or tricuspid regurgitation. 40% of patients presented stage >2 deterioration. 

Read also: EuroPCR 2025 | DANAMI-3-DEFER: 10-Year Results of Deferred vs. Conventional Stenting in STEMI Patients.

Mean time to TAVR was 14 days in ≤22 day patients and 33 days in the >22 group. 

There were no differences in valve type or hospital evolution. 

Patients were followed up to 4,6 (3,6–5,7) years. The primary outcome was seen in 58% of patients. Time to TAVR (for every 5-day delay) was significantly associated to the primary outcome (hazard ratio [HR], 1,09 [CI 95%, 1,03–1,14]; P=0,002). Also, >22 days to TAVR was associated to higher risk of adverse events (HR 1,48 [CI 95%, 1,09–2,03]; P=0,013).

Read also: Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes.

The was a significant link between the primary outcome and the presence of syncope, COPD, stroke, stage >2 and the need for cardiopulmonary support.

Conclusion

In patients with acute decompensated aortic stenosis, a longer wait to TAVR was associated to increased risk of events at mid-term. 

Original Title: Shorter Time to Transcatheter Aortic Valve Implantation Is Associated With Improved Outcomes in Acute Decompensated Aortic Stenosis.

Reference: Michael McKenna, et al. Circ Cardiovasc Interv. 2025;18:e014915. DOI: 10.1161/CIRCINTERVENTIONS.124.014915.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...